These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32796651)

  • 1. Heat Shock Protein 90 (Hsp90)-Inhibitor-Luminespib-Loaded-Protein-Based Nanoformulation for Cancer Therapy.
    K Rochani A; Balasubramanian S; Ravindran Girija A; Maekawa T; Kaushal G; Kumar DS
    Polymers (Basel); 2020 Aug; 12(8):. PubMed ID: 32796651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NIX protein enhances antioxidant capacity of and reduces the apoptosis induced by HSP90 inhibitor luminespib/NVP-AUY922 in PC12 cells.
    Zhang H; Ge F; Shui X; Xiang Y; Wang X; Liao C; Wang J
    Cell Stress Chaperones; 2021 May; 26(3):495-504. PubMed ID: 33629253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
    Augello G; Emma MR; Cusimano A; Azzolina A; Mongiovì S; Puleio R; Cassata G; Gulino A; Belmonte B; Gramignoli R; Strom SC; McCubrey JA; Montalto G; Cervello M
    Int J Cancer; 2019 May; 144(10):2613-2624. PubMed ID: 30488605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.
    Piotrowska Z; Costa DB; Oxnard GR; Huberman M; Gainor JF; Lennes IT; Muzikansky A; Shaw AT; Azzoli CG; Heist RS; Sequist LV
    Ann Oncol; 2018 Oct; 29(10):2092-2097. PubMed ID: 30351341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro.
    Epp-Ducharme B; Dunne M; Fan L; Evans JC; Ahmed L; Bannigan P; Allen C
    Sci Rep; 2021 May; 11(1):11103. PubMed ID: 34045581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer.
    Noor ZS; Goldman JW; Lawler WE; Telivala B; Braiteh F; DiCarlo BA; Kennedy K; Adams B; Wang X; Jones B; Slamon DJ; Garon EB
    Lung Cancer; 2019 Sep; 135():104-109. PubMed ID: 31446981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation.
    Rochani AK; Balasubramanian S; Ravindran Girija A; Raveendran S; Borah A; Nagaoka Y; Nakajima Y; Maekawa T; Kumar DS
    Int J Pharm; 2016 Sep; 511(1):648-658. PubMed ID: 27469073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
    Seggewiss-Bernhardt R; Bargou RC; Goh YT; Stewart AK; Spencer A; Alegre A; Bladé J; Ottmann OG; Fernandez-Ibarra C; Lu H; Pain S; Akimov M; Iyer SP
    Cancer; 2015 Jul; 121(13):2185-92. PubMed ID: 25809731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Selective are Hsp90 Inhibitors for Cancer Cells over Normal Cells?
    Wang Y; Koay YC; McAlpine SR
    ChemMedChem; 2017 Mar; 12(5):353-357. PubMed ID: 28139075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bovine Serum Albumin (BSA) coated iron oxide magnetic nanoparticles as biocompatible carriers for curcumin-anticancer drug.
    Nosrati H; Sefidi N; Sharafi A; Danafar H; Kheiri Manjili H
    Bioorg Chem; 2018 Feb; 76():501-509. PubMed ID: 29310081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer.
    Su YH; Tang WC; Cheng YW; Sia P; Huang CC; Lee YC; Jiang HY; Wu MH; Lai IL; Lee JW; Lee KH
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2261-72. PubMed ID: 25982393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A; Razifar P; Ide S; Rugaard Jensen M; Josephsson R; Blomqvist C; Langström B; Bergström M
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
    Canonici A; Qadir Z; Conlon NT; Collins DM; O'Brien NA; Walsh N; Eustace AJ; O'Donovan N; Crown J
    Invest New Drugs; 2018 Aug; 36(4):581-589. PubMed ID: 29396630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, in silico modelling and functionality theory of folate-receptor-targeted myricetin-loaded bovine serum albumin nanoparticle formulation for cancer treatment.
    Kunjiappan S; Govindaraj S; Parasuraman P; Sankaranarayanan M; Arunachalam S; Palanisamy P; Mohan UP; Babkiewicz E; Maszczyk P; Vellaisamy S; Panneerselvam T
    Nanotechnology; 2020 Apr; 31(15):155102. PubMed ID: 31775133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
    Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
    Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of biological nanoparticles from bovine serum albumin as controlled release carrier for curcumin delivery.
    Salehiabar M; Nosrati H; Javani E; Aliakbarzadeh F; Kheiri Manjili H; Davaran S; Danafar H
    Int J Biol Macromol; 2018 Aug; 115():83-89. PubMed ID: 29653171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
    Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
    Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
    Jorge SE; Lucena-Araujo AR; Yasuda H; Piotrowska Z; Oxnard GR; Rangachari D; Huberman MS; Sequist LV; Kobayashi SS; Costa DB
    Clin Cancer Res; 2018 Dec; 24(24):6548-6555. PubMed ID: 30154228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
    Moser C; Lang SA; Hackl C; Wagner C; Scheiffert E; Schlitt HJ; Geissler EK; Stoeltzing O
    Anticancer Res; 2012 Jul; 32(7):2551-61. PubMed ID: 22753713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.